Evidence map›Paper›PMID 32935120›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Metabolic programs define dysfunctional immune responses in severe COVID-19 patients.

Elizabeth A Thompson, Katherine Cascino, Alvaro A Ordonez, Weiqiang Zhou, Ajay Vaghasia, Anne Hamacher-Brady, Nathan R Brady, Im-Hong Sun, Rulin Wang, Avi Z Rosenberg and 16 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 25 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 2 institutions in 1 country.

Elizabeth A ThompsonDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Katherine CascinoDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Alvaro A OrdonezDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Weiqiang ZhouDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Ajay VaghasiaDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Anne Hamacher-BradyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Nathan R BradyW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Im-Hong SunDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Rulin WangDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Avi Z RosenbergDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Michael DelannoyDepartment of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Richard RothmanDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Katherine FenstermacherDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Lauren SauerDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kathyrn Shaw-SalibaDepartment of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Andrew D ReddDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Aaron Ar TobianDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Maureen HortonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Kellie SmithDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Franco R D'AlessioDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Srinivasan YegnasubramanianDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Hongkai JiDepartment of Biostatistics, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD 21287, USA.
Andrea L CoxDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Jonathan D PowellDepartment of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Johns Hopkins University · USBloomberg (United States) · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
TR&D Project 3P41EB028239 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI JONATHAN P SCHNECK · 2019 to 2026
$11.5M
Training Program In Cellular and Molecular MedicineT32GM135457 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAJINI RAO · 2020 to 2026
$5.4M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
Big Data Methods for Decoding Gene RegulationR01HG009518 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI JI, HONGKAI · 2018 to 2021
$1.7M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
A prospective evaluation of chronic B.microti infection in seroreactive blood donR21HL117140 · NHLBI · VITALANT · PI BLOCH, EVAN MARTIN · 2013 to 2014
$452k
LSM880 Laser-scanning Microscope with Airyscan ModuleS10OD023548 · OD · JOHNS HOPKINS UNIVERSITY · PI KUO, SCOT CHARLES · 2018 to 2018
$439k
NCATS NIH HHS UL1 TR001079NHGRI NIH HHS R01 HG009518NHLBI NIH HHS K23 HL151826NIAID NIH HHS HHSN272201400007CNIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIBIB NIH HHS P41 EB028239NIGMS NIH HHS T32 GM135457NIH HHS S10 OD023548
6 · The paper itself

Abstract

It remains unclear why some patients infected with SARS-CoV-2 readily resolve infection while others develop severe disease. To address this question, we employed a novel assay to interrogate immune-metabolic programs of T cells and myeloid cells in severe and recovered COVID-19 patients. Using this approach, we identified a unique population of T cells expressing high H3K27me3 and the mitochondrial membrane protein voltage-dependent anion channel (VDAC), which were expanded in acutely ill COVID-19 patients and distinct from T cells found in patients infected with hepatitis c or influenza and in recovered COVID-19. Increased VDAC was associated with gene programs linked to mitochondrial dysfunction and apoptosis. High-resolution fluorescence and electron microscopy imaging of the cells revealed dysmorphic mitochondria and release of cytochrome

Identifiers

PMID32935120
PMCPMC7491535
OpenAlexW3084697167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.